Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
01789 Ak Medical
7.960
+0.010+0.13%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Turnover
18.67% 531.21M -26.46% 761.44M -6.54% 447.63M 11.73% 1.04B
Operating income
18.67% 531.21M -26.46% 761.44M -6.54% 447.63M 11.73% 1.04B
Cost of sales
-38.32% -192.68M 18.26% -262.25M 2.35% -139.3M -13.19% -320.85M
Operating expenses
-38.32% -192.68M 18.26% -262.25M 2.35% -139.3M -13.19% -320.85M
Gross profit
9.80% 338.54M -30.14% 499.19M -8.32% 308.33M 11.08% 714.53M
Selling expenses
-26.67% -99.71M -21.57% -187.35M -25.45% -78.72M 12.11% -154.1M
Administrative expenses
-6.86% -54.54M -26.86% -105.32M -33.39% -51.04M 9.96% -83.02M
Research and development expenses
-5.15% -54.4M -7.71% -113.07M -17.85% -51.74M -30.36% -104.97M
Impairment and provision
-- -- -- -- -- -- -- -8.85M
-Goodwill impairment
-- -- -- -- -- -- -- -8.85M
Special items of operating profit
138.27% 4.96M 12.11% 5.98M 120.57% 2.08M -73.77% 5.33M
Operating profit
4.60% 134.84M -73.05% 99.44M -32.98% 128.92M 16.93% 368.93M
Financing income
442.55% 14.61M 18.77% 9.12M -40.35% 2.69M 30.61% 7.68M
Earning before tax
13.56% 149.45M -71.17% 108.56M -33.15% 131.61M 17.18% 376.61M
Tax
-16.35% -23.42M 74.54% -15.94M 40.80% -20.13M -15.05% -62.6M
After-tax profit from continuing operations
13.05% 126.03M -70.50% 92.62M -31.55% 111.48M 17.61% 314.01M
Earning after tax
13.05% 126.03M -70.50% 92.62M -31.55% 111.48M 17.61% 314.01M
Profit attributable to shareholders
13.05% 126.03M -70.50% 92.62M -31.55% 111.48M 17.61% 314.01M
Basic earnings per share
10.00% 0.11 -71.43% 0.08 -33.33% 0.1 7.69% 0.28
Diluted earnings per share
10.00% 0.11 -71.43% 0.08 -33.33% 0.1 12.00% 0.28
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--KPMG accounting firm--KPMG accounting firm

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Aikang Medical Holdings Limited ("Aikang Medical" or "Company") commercializes and applies 3D printing technology to implants in bone, joint and spinal replacements, and occupies a leading position in the bone and joint implants market in China. Aikang Medical designs, develops, produces and sells orthopedic implants, and specializes in hip and knee replacement implants. Aikang Medical's products include bone and joint implants for primary surgery and bone joint implants specially designed for the replacement, repair or upgrading of implants or components of previous operations. Aikang Medical also sells orthopaedic products produced by third parties as a distributor to complement the product portfolio provided by the company to its customers. Aikang Medical sells its products under the brand name "Aikang". After years of development, it has become a best-selling brand of intra-articular implants in China. In terms of revenue in 2017, Aikang is also a best-selling brand of intra-articular implants in China. Aikang Medical developed a personalized 3D precision construction technology solution ("3D ACT solution") in July 2014. 3D ACT solutions help surgeons simulate and plan operations, simplify surgical procedures, provide personalized surgical instruments and selected implants before surgery, and significantly improve patient recovery. Aikang Medical's regular products and 3D printing products are regulated by the Food and Drug Administration. Currently, the company's three 3D printing products include hip replacement implants, spinal interbody fusion cages and artificial vertebrae. Aikang Medical is an one-stop orthopedic surgery solution company that combines all four services, including 3D imaging and 3D modeling, providing 3D printed models and customized surgical plans for patients, producing 3D printed surgical instruments and 3D printed implants for bone and joint replacement. Aikang Medical has an extensive and growing national distribution network. As of December 31, 2017, Aikang Medical's products have more than 650 distributors, covering all provinces in China and 23 overseas jurisdictions. The company also sells some of its products directly to hospitals through wholly-owned subsidiaries holding the relevant distributor licence. The company mainly maintains these direct sales to establish and maintain direct contacts with some of the company's major terminal hospital customers and surgeons.
CEO: Zhijiang Li
Market: Hong Kong motherboard
Listing Date: 12/20/2017
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist